Market Cap 25.78B
Revenue (ttm) 9.68B
Net Income (ttm) 1.63B
EPS (ttm) N/A
PE Ratio 10.40
Forward PE 11.68
Profit Margin 16.87%
Debt to Equity Ratio 0.35
Volume 2,408,400
Avg Vol 1,793,758
Day's Range N/A - N/A
Shares Out 146.70M
Stochastic %K 16%
Beta 0.13
Analysts Sell
Price Target $179.78

Company Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar refer...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 617 679 2000
Address:
225 Binney Street, Cambridge, United States
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 2:40 AM
Actionable Trade Alert for $BIIB: Market Context: $BIIB is currently trading at $171.57, showing a potential for upward movement given its recent low RSI of 32.08, indicating oversold conditions. The stock is also positioned above its 30-day moving average (MA30) of 170.73, suggesting a bullish sentiment may be developing. Directional Bias: The RSI indicates that the stock is oversold, while the price is near the 60D low of 135.39, providing a favorable risk-reward scenario for a bounce back. The MA50 at 161.67 supports this bullish outlook. Trade Plan: - Suggested Entry: $172.00 - Stop Loss: $165.00 (4.5% risk) - Take Profit Targets: 1. $180.00 (4.7% gain) 2. $185.00 (7.8% gain) 3. $200.00 (16.6% gain) With these targets, the third take profit offers a potential ROI of over 17%. Monitor price action closely for optimal entry. https://privateprofiteers.com
0 · Reply
Est1er_Holmes
Est1er_Holmes Dec. 16 at 4:35 PM
$BIIB SBFM cash-heavy balance + growing top line… that’s not typical microcap
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 16 at 2:48 PM
Enter: $BIIB Calls Strike Price: $175 Expiry Date: JAN 09 2026 Buy in Price: $5.50 - $5.60 Sell Price: $8.74 Profit : +56% (Turn every $1 into $1.56) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Quantumup
Quantumup Dec. 16 at 2:04 PM
H.C. Wainwright⬆️ $STOK's PT to $50 from $35 and reiterated at Buy $BIIB $UCBJY UCBJF $JAZZ $PRAX H.C. Wainwright said—Zorevunersen's rigorous propensity-weighted analysis reveals a clinically transformative ~82% seizure reduction and significant cognitive gains, substantially de-risking the Phase 3 EMPEROR study which is powered for far more modest improvements. With strong KOL validation supporting its use in severe patients despite safety signals, and new data expanding the addressable market to "Atypical Dravet," Stoke offers a scientifically validated "root cause" opportunity with significant regulatory upside. Therefore, given the data, the potential of zorevunersen for atypical Dravet patients, and the KOL validation, we revisited our PoS assumptions, and our penetration assumptions, which increases our PT from $35 to $50.
0 · Reply
dogDazeSummer
dogDazeSummer Dec. 16 at 2:02 PM
$IFRX this little piggy going to market to by .97 x 9900 x? Premakrt. Let’s see how big sellers are. If $BIIB paid $100M + $900M “bio bucks” - I’m ok w $80M total. NFA!
0 · Reply
howardlindzon
howardlindzon Dec. 16 at 3:08 AM
$LULU $TTD and $BIIB out of the $QQQ ... Interesting
3 · Reply
RunnerSignals
RunnerSignals Dec. 15 at 9:33 PM
Dip-to-Rip! $KO $BIIB $AVXL $FGNX $AIRS started shaky but bounced hard today good job!
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 6:13 AM
Actionable Trade Alert for $BIIB: Market Context: $BIIB closed at $174.1, positioned within a range defined by a 60D High of $185.17 and a 60D Low of $135.39. The current RSI of 47.99 indicates neutral momentum, suggesting potential for upward movement as it approaches oversold territory. Directional Bias: Given the proximity to the MA30 (169.35) and the MA50 (161.0), there is a bullish bias as the price is above both moving averages, indicating a potential upward trend. The ATR of 5.4 suggests moderate volatility, allowing for reasonable price movement. Trade Plan: - Suggested Entry: $175.00 - Stop Loss: $168.00 (4.5% risk) - Take Profit Targets: 1. $180.00 (2.86% ROI) 2. $185.00 (5.69% ROI) 3. $204.00 (17.19% ROI) This plan provides a structured approach to capitalize on potential upward momentum while managing risk effectively. https://privateprofiteers.com
0 · Reply
dogDazeSummer
dogDazeSummer Dec. 14 at 6:27 PM
$IFRX $MLTX $INCY $BIIB https://www.dermatologytimes.com/view/global-hidradenitis-suppurativa-atlas-ghisa-finds-hs-affects-1-of-the-world-s-population?utm_content=361519958&utm_medium=social&utm_source=twitter&hss_channel=tw-55642575 “Our analysis confirms that HS affects far more people than previously thought, and this has profound implications for awareness, screening, and resource allocation,” she said.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 14 at 4:15 PM
Enter: $BIIB Calls Strike Price: $190 Expiry Date: JAN 09 2026 Buy in Price: $1.08 - $2.90 Sell Price: $2.31 Profit : +114% (Turn every $1 into $2.14) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Latest News on BIIB
AI Stocks Are Taking a Beating. What to Buy Instead.

Nov 21, 2025, 1:13 PM EST - 25 days ago

AI Stocks Are Taking a Beating. What to Buy Instead.

AKAM AMZN EXPE LLY


Biogen Completes Acquisition of Alcyone Therapeutics

Nov 14, 2025, 4:05 PM EST - 4 weeks ago

Biogen Completes Acquisition of Alcyone Therapeutics

IONS


Biogen Inc. (BIIB) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 9:16 PM EDT - 6 weeks ago

Biogen Inc. (BIIB) Q3 2025 Earnings Call Transcript


Biogen's Comeback: Why The Bulls Are Finally Winning Again

Oct 9, 2025, 10:54 AM EDT - 2 months ago

Biogen's Comeback: Why The Bulls Are Finally Winning Again


BIIB Stock: Is Biogen Still A Buy After The 14% Spike?

Oct 3, 2025, 8:50 AM EDT - 2 months ago

BIIB Stock: Is Biogen Still A Buy After The 14% Spike?


PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 2:40 AM
Actionable Trade Alert for $BIIB: Market Context: $BIIB is currently trading at $171.57, showing a potential for upward movement given its recent low RSI of 32.08, indicating oversold conditions. The stock is also positioned above its 30-day moving average (MA30) of 170.73, suggesting a bullish sentiment may be developing. Directional Bias: The RSI indicates that the stock is oversold, while the price is near the 60D low of 135.39, providing a favorable risk-reward scenario for a bounce back. The MA50 at 161.67 supports this bullish outlook. Trade Plan: - Suggested Entry: $172.00 - Stop Loss: $165.00 (4.5% risk) - Take Profit Targets: 1. $180.00 (4.7% gain) 2. $185.00 (7.8% gain) 3. $200.00 (16.6% gain) With these targets, the third take profit offers a potential ROI of over 17%. Monitor price action closely for optimal entry. https://privateprofiteers.com
0 · Reply
Est1er_Holmes
Est1er_Holmes Dec. 16 at 4:35 PM
$BIIB SBFM cash-heavy balance + growing top line… that’s not typical microcap
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 16 at 2:48 PM
Enter: $BIIB Calls Strike Price: $175 Expiry Date: JAN 09 2026 Buy in Price: $5.50 - $5.60 Sell Price: $8.74 Profit : +56% (Turn every $1 into $1.56) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Quantumup
Quantumup Dec. 16 at 2:04 PM
H.C. Wainwright⬆️ $STOK's PT to $50 from $35 and reiterated at Buy $BIIB $UCBJY UCBJF $JAZZ $PRAX H.C. Wainwright said—Zorevunersen's rigorous propensity-weighted analysis reveals a clinically transformative ~82% seizure reduction and significant cognitive gains, substantially de-risking the Phase 3 EMPEROR study which is powered for far more modest improvements. With strong KOL validation supporting its use in severe patients despite safety signals, and new data expanding the addressable market to "Atypical Dravet," Stoke offers a scientifically validated "root cause" opportunity with significant regulatory upside. Therefore, given the data, the potential of zorevunersen for atypical Dravet patients, and the KOL validation, we revisited our PoS assumptions, and our penetration assumptions, which increases our PT from $35 to $50.
0 · Reply
dogDazeSummer
dogDazeSummer Dec. 16 at 2:02 PM
$IFRX this little piggy going to market to by .97 x 9900 x? Premakrt. Let’s see how big sellers are. If $BIIB paid $100M + $900M “bio bucks” - I’m ok w $80M total. NFA!
0 · Reply
howardlindzon
howardlindzon Dec. 16 at 3:08 AM
$LULU $TTD and $BIIB out of the $QQQ ... Interesting
3 · Reply
RunnerSignals
RunnerSignals Dec. 15 at 9:33 PM
Dip-to-Rip! $KO $BIIB $AVXL $FGNX $AIRS started shaky but bounced hard today good job!
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 6:13 AM
Actionable Trade Alert for $BIIB: Market Context: $BIIB closed at $174.1, positioned within a range defined by a 60D High of $185.17 and a 60D Low of $135.39. The current RSI of 47.99 indicates neutral momentum, suggesting potential for upward movement as it approaches oversold territory. Directional Bias: Given the proximity to the MA30 (169.35) and the MA50 (161.0), there is a bullish bias as the price is above both moving averages, indicating a potential upward trend. The ATR of 5.4 suggests moderate volatility, allowing for reasonable price movement. Trade Plan: - Suggested Entry: $175.00 - Stop Loss: $168.00 (4.5% risk) - Take Profit Targets: 1. $180.00 (2.86% ROI) 2. $185.00 (5.69% ROI) 3. $204.00 (17.19% ROI) This plan provides a structured approach to capitalize on potential upward momentum while managing risk effectively. https://privateprofiteers.com
0 · Reply
dogDazeSummer
dogDazeSummer Dec. 14 at 6:27 PM
$IFRX $MLTX $INCY $BIIB https://www.dermatologytimes.com/view/global-hidradenitis-suppurativa-atlas-ghisa-finds-hs-affects-1-of-the-world-s-population?utm_content=361519958&utm_medium=social&utm_source=twitter&hss_channel=tw-55642575 “Our analysis confirms that HS affects far more people than previously thought, and this has profound implications for awareness, screening, and resource allocation,” she said.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 14 at 4:15 PM
Enter: $BIIB Calls Strike Price: $190 Expiry Date: JAN 09 2026 Buy in Price: $1.08 - $2.90 Sell Price: $2.31 Profit : +114% (Turn every $1 into $2.14) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
BioTechHealthX
BioTechHealthX Dec. 13 at 11:21 PM
$BIIB Biogen Inc. has spent decades focusing on diseases of the brain and spinal cord, building scientific platforms that target protein aggregation, RNA splicing, and neurodegeneration. https://biotechhealthx.com/biotech-news/how-biogen-inc-biib-built-one-of-biotechs-most-specialized-neuroscience-platforms/
0 · Reply
RunnerSignals
RunnerSignals Dec. 13 at 9:01 PM
Behind the Paywall Some pullbacks whisper, others set traps. $OVV $GOOG $BIIB $MNST $KO are dipping but still trending up. full breakdown and best near-term setup inside for pro subscribers only https://stocksrunner.com/news/2025-12-13-stocks-ready-to-bounce-back-after-pullbacks
0 · Reply
JarvisFlow
JarvisFlow Dec. 12 at 5:07 PM
Morgan Stanley has adjusted their stance on Biogen ( $BIIB ), setting the rating to Equal-Weight with a target price of 149 → 156.
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 12 at 2:18 PM
Enter: $BIIB Calls Strike Price: $180 Expiry Date: JAN 02 2026 Buy in Price: $2.21 - $5.30 Sell Price: $4.57 Profit : +107% (Turn every $1 into $2.07) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 11:07 PM
Actionable Trade Alert for $BIIB: Market Context: $BIIB closed at $179.09, showing strength but nearing overbought territory with an RSI of 67.12. The stock is above both the 30-day MA (168.75) and 50-day MA (160.76), indicating bullish momentum. The 60-day high of $185.17 presents a key resistance level, while the low of $135.39 offers support. Directional Bias: The bullish trend is supported by the stock's position above the moving averages, but caution is warranted due to the RSI approaching overbought levels. Trade Plan: - Suggested Entry: $179.50 - Stop Loss: $173.00 (3.5% risk) - Take Profit Targets: 1. $185.00 (3.3% gain) 2. $190.00 (5.9% gain) 3. $210.00 (17.3% gain) This plan offers a potential ROI of over 17% on the third target while maintaining a reasonable risk-reward ratio. Monitor the stock closely for volatility as indicated by the ATR of 5.49. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
jarbou3
jarbou3 Dec. 11 at 9:08 PM
$BIIB If you followed that lousy HSBC analyst y'd make negative 24% return last year.
0 · Reply
JarvisFlow
JarvisFlow Dec. 10 at 8:03 PM
Wells Fargo has updated their rating for Biogen ( $BIIB ) to Equal-Weight with a price target of 190.
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Dec. 10 at 3:55 PM
0 · Reply
Quantumup
Quantumup Dec. 10 at 3:23 PM
Cantor yesterday reiterated $LXEO Overweight/$19 after Lexeo Therapeutics Hosted a Virtual Key Opinion Leader (KOL) Event, “A Clinician’s Perspective: Holistic Approach to Managing PKP2-Associated Arrhythmogenic Cardiomyopathy,” at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum. $RCKT $TNYA $LRMR $BIIB Cantor said in its note to investors: While there is significant investor attention on the lead program in Friedreich's ataxia, we believe the PKP2-ACM program is still under the radar; this upcoming data in January may change that narrative. Today's event helped to clarify how amenable this patient population could be to a gene therapy approach, especially as it relates to the impact of traumatic cardiac events that could motivate patients to get a potential one-time approach. Even if we conservatively assumed just 5,000 patients (a single-digit percentage of the market size) received this therapy, that is cumulative potential sales of $10B alone.
0 · Reply
StockBraker
StockBraker Dec. 10 at 2:17 PM
$BIIB HSBC lowers by $ 1 and issues a Reduce call. Overall sentiment from 23 analysts covering is still Buy and a 12-month, consensus price target of $181.72 with a high of $250 from Baird issued in late Oct.
1 · Reply
Quantumup
Quantumup Dec. 10 at 12:06 PM
Oppenheimer reiterated $LXEO Outperform/$20 $RCKT $TNYA $LRMR $BIIB Oppenheimer said: Lexeo Therapeutics held a virtual event with an academic cardiologist yesterday to discuss PKP2-ACM, its current management, and how LX2020 may fit into treatment. The expert emphasized shortcomings of current care standards for this rare, inherited, and progressive cardiac disorder that frequently first presents with sudden cardiac arrest. With no disease-modifying options available, transplant may be eventually required. She estimated that ~70% of patients referred to her would be gene therapy candidates and that patient willingness to receive such would be high after a major arrhythmic event. While investors have mainly focused on LX2006's opportunity in Friedrich's ataxia, January's substantive interim safety and efficacy look from LX2020's Phase 1/2's low- and high-dose cohorts could drive better appreciation of LXEO's opportunity in PKP2-ACM.
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Dec. 10 at 12:00 PM
$BIIB HSBC Downgrades Biogen to Reduce, Lowers Price Target to $143
0 · Reply